Immunome (IMNM) Stock Price Target 2026

The average analyst price target for Immunome is $32, 72.0% above the current price. Of 17 analysts, 16 rate it Buy and 1 Hold. Targets range from $20 to $40. The latest change came on Nov 10, 2026, when Piper Sandler lowered its price target on Immunome from $33 to $30 and kept an Overweight rating.

The Average Analyst Price Target for Immunome is $32.

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

16Buy

1Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$32Upside to Avg. PT+72.0%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Immunome Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 10, 2026	Piper Sandler	Biren Amin	PT Cut	Overweight	$33→$30
Nov 10, 2026	Stifel	Dara Azar	PT Cut	Hold	$24→$23
Oct 27, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$35
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 1, 2026	Stifel	Dara Azar	Initiate	Hold	$24
Sep 21, 2026	Alliance Global Partners	Matthew Venezia	Initiate	Buy	$32
Sep 10, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Aug 12, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$37→$38
Aug 12, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$31→$35
Jul 21, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
Jun 12, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
May 28, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$36→$37
May 28, 2026	Barclays	Lukas Shumway	Initiate	Overweight	$36
May 15, 2026	Leerink Partners	Andrew Berens	PT Cut	Outperform	$37→$33
May 13, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Mar 4, 2026	Craig-Hallum	Adam Vogel	PT Raise	Buy	$33→$36
Mar 4, 2026	Stephens & Co.	Sudan Loganathan	PT Cut	Overweight	$33→$30
Feb 12, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Initiate	Buy	$40
Jan 15, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
Dec 16, 2025	Lake Street	Chad Messer	PT Raise	Buy	$22→$32